JP2010530362A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530362A5
JP2010530362A5 JP2010510239A JP2010510239A JP2010530362A5 JP 2010530362 A5 JP2010530362 A5 JP 2010530362A5 JP 2010510239 A JP2010510239 A JP 2010510239A JP 2010510239 A JP2010510239 A JP 2010510239A JP 2010530362 A5 JP2010530362 A5 JP 2010530362A5
Authority
JP
Japan
Prior art keywords
hpv
amino acid
derived
protein
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010510239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2008/050315 external-priority patent/WO2009002159A2/en
Publication of JP2010530362A publication Critical patent/JP2010530362A/ja
Publication of JP2010530362A5 publication Critical patent/JP2010530362A5/ja
Pending legal-status Critical Current

Links

JP2010510239A 2007-05-31 2008-05-27 皮内hpvペプチドワクチン接種 Pending JP2010530362A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94107007P 2007-05-31 2007-05-31
EP07109287 2007-05-31
PCT/NL2008/050315 WO2009002159A2 (en) 2007-05-31 2008-05-27 Intradermal hpv peptide vaccination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014133168A Division JP5888823B2 (ja) 2007-05-31 2014-06-27 皮内hpvペプチドワクチン接種

Publications (2)

Publication Number Publication Date
JP2010530362A JP2010530362A (ja) 2010-09-09
JP2010530362A5 true JP2010530362A5 (enExample) 2011-06-30

Family

ID=38477016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010510239A Pending JP2010530362A (ja) 2007-05-31 2008-05-27 皮内hpvペプチドワクチン接種
JP2014133168A Expired - Fee Related JP5888823B2 (ja) 2007-05-31 2014-06-27 皮内hpvペプチドワクチン接種

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014133168A Expired - Fee Related JP5888823B2 (ja) 2007-05-31 2014-06-27 皮内hpvペプチドワクチン接種

Country Status (10)

Country Link
US (2) US9562075B2 (enExample)
EP (1) EP2155240B1 (enExample)
JP (2) JP2010530362A (enExample)
CN (1) CN101795705A (enExample)
AU (1) AU2008269721B2 (enExample)
BR (1) BRPI0812311A8 (enExample)
CA (1) CA2688589A1 (enExample)
ES (1) ES2482192T3 (enExample)
MX (1) MX2009012922A (enExample)
WO (1) WO2009002159A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468763B1 (en) * 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
CA2731444A1 (en) * 2008-09-02 2010-03-11 Antigen Express, Inc. Human papillomavirus / li-key hybrids and methods of use
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスBionor Immuno As ペプチド骨格設計
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
JP7092662B2 (ja) 2015-10-30 2022-06-28 チルドレンズ ナショナル メディカル センター ナイーブt細胞集団からのhpv抗原特異的t細胞の生成
CN108430505A (zh) 2015-11-18 2018-08-21 免疫疫苗技术有限公司 包括聚肌胞苷酸多核苷酸佐剂和基于脂质的佐剂的辅助系统以及无水疫苗组合物
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
US11524063B2 (en) * 2017-11-15 2022-12-13 Arizona Board Of Regents On Behalf Of Arizona State University Materials and methods relating to immunogenic epitopes from human papillomavirus
CA3093826A1 (en) * 2018-03-12 2019-09-19 Sqz Biotechnologies Company Methods for treating hpv-associated diseases
EP3765068A2 (en) * 2018-03-12 2021-01-20 SQZ Biotechnologies Company Intracellular delivery of biomolecules to modify immune response
US11065317B2 (en) * 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
JP2024503277A (ja) * 2020-12-29 2024-01-25 スクイーズ バイオテクノロジーズ カンパニー 活性化抗原担体の製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US5932412A (en) 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
DE9106105U1 (de) * 1991-05-17 1991-09-26 Behringwerke Ag, 3550 Marburg Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
JP2000503003A (ja) * 1995-12-22 2000-03-14 イムノメディクス,インコーポレイテッド 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
AU765822B2 (en) 1998-05-23 2003-10-02 Leiden University Medical Center CD40 binding molecules and CTL peptides for treating tumors
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6641994B2 (en) 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
CA2431500C (en) * 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
WO2003008649A1 (en) * 2001-07-20 2003-01-30 Board Of Regents, The University Of Texas System Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
US6884605B2 (en) * 2001-08-09 2005-04-26 Board Of Trustees Of The University Of Arkansas Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
EP1708745B1 (en) 2003-12-23 2012-04-18 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US20090028874A1 (en) * 2003-12-24 2009-01-29 Leiden University Medical Center Synthetic Protein as Tumor-Specific Vaccine
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
DE602006021408D1 (de) * 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Similar Documents

Publication Publication Date Title
JP2010530362A5 (enExample)
Wu et al. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
Meyer et al. Clinical investigations of Toll-like receptor agonists
Lin et al. Therapeutic hpv DNA vaccines
JP6811014B2 (ja) B型肝炎ウイルスに対するワクチン
JP5230891B2 (ja) 抗原特異的t細胞の新規な誘導方法
Zhang et al. Effects of astragalus polysaccharide on the immune response to foot-and-mouth disease vaccine in mice
CN1678344A (zh) 人乳头状瘤病毒治疗
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US10233215B2 (en) Peptide and use thereof
JP2009541373A5 (enExample)
RU2011123700A (ru) Нонапептид с противоопухолевой активностью
Chuang et al. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
JP2014508734A5 (enExample)
KR20200027956A (ko) 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
WO2005060993A1 (en) Synthetic protein as tumor-specific vaccine
JP2022172244A5 (enExample)
Tseng et al. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination
JP2010506926A5 (enExample)
US8470372B2 (en) Material with immunogenicity
Pokorná et al. Vaccination with human papillomavirus type 16-derived peptides using a tattoo device
Peng et al. Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
KR100904844B1 (ko) 인유두종 바이러스(hpv)유전자를 포함하는자궁경부암의 치료 또는 예방용 dna 백신
JP2012501351A5 (enExample)
CN105732780B (zh) 一种枯草颖肽素及其应用